AOD-9604 — pharmacology
Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.
§2Pharmacology
§2.1Molecular targets
Table 2. Molecular targets recorded for AOD-9604, with the character of the interaction and the potency where the Institute holds it.
| Target | Interaction | Note |
|---|---|---|
| Mechanism not established | Not a defined receptor agonist | Preclinical work describes beta-3 adrenoceptor-dependent effects in rodent adipose tissue that have not been reproduced in human tissue |
§2.2Mechanism of action
The proposed mechanism is stimulation of lipolysis and inhibition of lipogenesis in adipose tissue without the growth-hormone-receptor-mediated effects on IGF-1, glucose tolerance or tissue growth. The Institute notes that no defined human molecular target has been established, and that the rodent findings depend on a beta-3 adrenoceptor pathway whose human counterpart differs substantially in expression and pharmacology.[1,2]
§2.3Pharmacokinetics
- Terminal half-life
- not reliably established in humans
- Time to maximum concentration
- not published
- Volume of distribution
- not published
- Plasma protein binding
- not published
- Clearance
- not published
- Bioavailability
- the clinical programme used an oral route, implying either systemic absorption of a 1815 Da disulfide-containing peptide or a local mechanism; neither has been demonstrated
Not characterised.
§2.4Interactions
- Not characterised
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522 · PMID 11713213
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.